Table II.
Impact of the different risk prognostic models in Overall Survival in CMML patients treated with hypomethylating agents.
|
|
||||
|---|---|---|---|---|
| Kaplan-Meier for OS (months) | Cox-Regression for OS | |||
| Median (95%CI) | p | HR (95%CI) | p | |
| CPSS | ||||
| Low | 75.3 (0.0–165.5) | <0.001 | ||
| Intermediate-1 | 24.4 (13.7–35.0) | <0.001 | 1.93 (0.85–4.40) | <0.001 |
| Intermediate-2 | 18.1 (11.8–24.4) | 2.64 (1.17–5.94) | <0.001 | |
| High | 6.1 (0.0–13.1) | 8.51 (3.15–22.99) | 0.02 | |
|
| ||||
| MDAPS | ||||
| Low | 41.2 (31.9–50.1) | <0.001 | ||
| Intermediate-1 | 23.9 (18.9–28.9) | 1.42 (0.88–2.28) | 0.152 | |
| Intermediate-2 | 9.8 (6.7–12.9) | <0.001 | 4.16 (2.41–7.17) | <0.001 |
| High | 11.7 (2.6–20.8) | 5.08 (2.46–10.49) | <0.001 | |
|
| ||||
| MCPS | ||||
| Low | 43.2 (28.7–57.7) | <0.001 | ||
| Intermediate | 26.5 (14.7–38.0) | <0.001 | 1.37 (0.68–2.74) | 0.375 |
| High | 15.4 (9.3–21.5) | 3.40 (1.64–7.05) | <0.001 | |
|
| ||||
| IPSS | ||||
| Low | 16.0 (13.2–18–8) | 0.188 | ||
| Intermediate-1 | 26.7 (21.9–31.4) | 0.181 | 0.59 (0.35–0.99) | 0.049 |
| Intermediate-2 | 20.4 (11.3–29.5) | 0.80 (0.46–1.40) | 0.436 | |
| High | 9.0 (5.0–13.1) | 1.05 (0.36–3.05) | 0.935 | |
CMML: chronic myelomonocytic leukemia; OS: Overall survival; OR: Odds ratio; CPSS: CMML-specific prognostic scoring system; MDAPS: MD Anderson Cancer Center Prognostic Score System; MCPS: Mayo Clinic Prognostic Score; IPSS: international prognostic score system.